AG
ZVRA icon

Advisor Group’s Zevra Therapeutics ZVRA Stock Holding History

Advisor Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$1K Hold
125
– – ﹤0.01% 5216
2019
Q3 		$1K Hold
125
– – ﹤0.01% 5187
2019
Q2 		$4K Hold
125
– – ﹤0.01% 4793
2019
Q1 		$3K Hold
125
– – ﹤0.01% 4876
2018
Q4 		$4K Buy
125
+62
+98% +$2.51K ﹤0.01% 4643
2018
Q3 		$5K Hold
63
– – ﹤0.01% 4615
2018
Q2 		$7K Hold
63
– – ﹤0.01% 4267
2018
Q1 		$8K Hold
63
– – ﹤0.01% 4224
2017
Q4 		$4K Hold
63
– – ﹤0.01% 4519
2017
Q3 		$4K Hold
63
– – ﹤0.01% 4369
2017
Q2 		$4K Hold
63
– – ﹤0.01% 4349
2017
Q1 		$5K Buy
+63
New +$3.83K ﹤0.01% 4133

Other funds holding ZVRA

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RFN
RDA Financial Network Akron, Iowa $459M AUM 24.58% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Advisor Group's ZVRA Position: Q4 2019 in Review

Advisor Group held its Zevra Therapeutics (ZVRA) position steady in Q4 2019 at 125 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #5216.

Advisor Group first reported a position in ZVRA in Q1 2017 and has held it in 12 quarters since. The position peaked at $8K in Q1 2018. 27 funds tracked by Wall St. Rank hold ZVRA as of Q4 2019.

  • Advisor Group held 125 shares of Zevra Therapeutics worth $1K as of Q4 2019.
  • Advisor Group left its Zevra Therapeutics share count unchanged in Q4 2019.
  • Zevra Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5216 holding.
  • Advisor Group first reported a position in Zevra Therapeutics in Q1 2017 and has held it in 12 quarters since.
  • Advisor Group's Zevra Therapeutics position peaked at $8K in Q1 2018.
  • 27 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.